Insulet’s latest earnings call carried an upbeat tone, with management emphasizing powerful revenue growth, expanding margins, and a fast-advancing product pipeline. While executives acknowledged ...

Insulet reported revenue of $761.7 million for the first quarter of 2026, an increase of 33.9% over the prior year. Total Omnipod revenue was $758.4 million, up 36.9%.

Insulet (NASDAQ:PODD) reported what executives described as a “strong start” to fiscal 2026, posting double-digit revenue ...

Good morning, and welcome to the Insulet Corporation First Quarter Earnings Call. As a reminder, this conference call is being recorded. I would now like to turn the conference over to your host, ...

U.S. growth of 28% was supported by strong type 2 momentum, though results were tempered by higher-than-normal Q1 seasonality ...

Q1 2026 earnings call recap: raised revenue growth guidance, Omnipod 5 Libre 3 Plus integration, margins, risks & Q2 headwind—read now.

Insulet (Nasdaq:PODD) today reported first-quarter financial results that came in well ahead of the consensus forecast on ...

Indicated for people with Type 2 diabetes, the system would be Insulet’s first fully automated device for insulin delivery.

Insulet enrolled the first participant in a study of its fully closed-loop automated insulin delivery system for type 2 ...

In 2024, Insulet shared results from its landmark SECURE-T2D pivotal trial, demonstrating improved glycemic outcomes with Omnipod 5 compared with prior insulin injection or pump therapy in adults with ...

Forbes contributors publish independent expert analyses and insights. Gary Drenik is a writer covering AI, analytics and innovation. This voice experience is generated by AI. Learn more. This voice ...

Abstract: Based on the development needs of Industry 5.0, Advanced On-orbit Systems (AOS) can be integrated with terrestrial 5G networks, with large-scale Internet of Things (IoT) links as well as ...